Metropolitan Life Insurance CO Seres Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$4.67 - $6.55 $6,948 - $9,746	1,488 Added 38.73%	5,330 $25,000
Q1 2023 May 15, 2023	SELL	$4.95 - $6.09 $2,088 - $2,569	-422 Reduced 9.9%	3,842 $21,000
Q4 2022 Jun 14, 2023	BUY	$5.09 - $9.05 $2,147 - $3,819	422 Added 10.98%	4,264 $23.9 Million
Q3 2022 Jun 14, 2023	BUY	$3.5 - $7.2 $1,477 - $3,038	422 Added 10.98%	4,264 $27.4 Million
Q3 2022 Mar 30, 2023	BUY	$3.5 - $7.2 $9,943 - $20,455	2,841 Added 199.65%	4,264 $27,000
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $9,943 - $20,455	2,841 Added 199.65%	4,264 $27,000
Q2 2022 Jun 20, 2023	SELL	$2.7 - $7.62 $6,531 - $18,432	-2,419 Reduced 62.96%	1,423 $4,000
Q2 2022 Mar 30, 2023	SELL	$2.7 - $7.62 $8,748 - $24,688	-3,240 Reduced 69.48%	1,423 $4,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $7.62 $8,748 - $24,688	-3,240 Reduced 69.48%	1,423 $5,000
Q1 2022 Jun 20, 2023	BUY	$6.3 - $8.84 $5,172 - $7,257	821 Added 21.37%	4,663 $33,000
Q1 2022 Mar 30, 2023	SELL	$6.3 - $8.84 $57,632 - $80,868	-9,148 Reduced 66.24%	4,663 $33,000
Q1 2022 May 12, 2022	SELL	$6.3 - $8.84 $57,632 - $80,868	-9,148 Reduced 66.24%	4,663 $33,000
Q4 2021 Jun 21, 2023	BUY	$6.02 - $11.43 $60,013 - $113,945	9,969 Added 259.47%	13,811 $115,000
Q4 2021 Mar 30, 2023	BUY	$6.02 - $11.43 $23,213 - $44,074	3,856 Added 38.73%	13,811 $115,000
Q4 2021 Feb 15, 2022	BUY	$6.02 - $11.43 $23,213 - $44,074	3,856 Added 38.73%	13,811 $115,000
Q3 2021 Jun 21, 2023	BUY	$5.46 - $22.6 $33,376 - $138,153	6,113 Added 159.11%	9,955 $69,000
Q3 2021 Mar 30, 2023	SELL	$5.46 - $22.6 $52,110 - $215,694	-9,544 Reduced 48.95%	9,955 $69,000
Q3 2021 Nov 15, 2021	SELL	$5.46 - $22.6 $52,110 - $215,694	-9,544 Reduced 48.95%	9,955 $69,000
Q2 2021 Jun 21, 2023	BUY	$18.46 - $24.36 $289,028 - $381,404	15,657 Added 407.52%	19,499 $465,000
Q2 2021 Mar 30, 2023	BUY	$18.46 - $24.36 $85,469 - $112,786	4,630 Added 31.14%	19,499 $465,000
Q2 2021 Aug 16, 2021	BUY	$18.46 - $24.36 $359,674 - $474,630	19,484 Added 129893.33%	19,499 $465,000
Q1 2021 Jun 26, 2023	BUY	$17.66 - $28.92 $194,736 - $318,900	11,027 Added 287.01%	14,869 $306 Million
Q1 2021 Mar 30, 2023	SELL	$17.66 - $28.92 $13,545 - $22,181	-767 Reduced 4.91%	14,869 $306,000
Q1 2021 May 14, 2021	SELL	$17.66 - $28.92 $275,866 - $451,759	-15,621 Reduced 99.9%	15 $306,000
Q4 2020 Jun 22, 2023	BUY	$23.25 - $37.73 $274,210 - $444,987	11,794 Added 306.98%	15,636 $383,000
Q3 2020 Jun 26, 2023	BUY	$3.74 - $28.74 $44,109 - $338,959	11,794 Added 306.98%	15,636 $442,000
Q3 2020 Mar 30, 2023	SELL	$3.74 - $28.74 $418 - $3,218	-112 Reduced 0.71%	15,636 $442,000
Q3 2020 Nov 13, 2020	SELL	$3.74 - $28.74 $418 - $3,218	-112 Reduced 0.71%	15,636 $443,000
Q2 2020 Jun 26, 2023	BUY	$3.04 - $6.2 $36,194 - $73,817	11,906 Added 309.89%	15,748 $74,000
Q2 2020 Mar 30, 2023	BUY	$3.04 - $6.2 $34,911 - $71,200	11,484 Added 269.32%	15,748 $74,000
Q2 2020 Aug 14, 2020	BUY	$3.04 - $6.2 $47,873 - $97,637	15,748 New	15,748 $75,000
Q4 2017 Feb 15, 2018	SELL	$9.15 - $12.64 $143,115 - $197,702	-15,641 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	15,641	15,641 $177,000

Others Institutions Holding MCRB

# of Institutions

Shares Held

40.5M

Call Options Held

304K

Put Options Held

471K

Flagship Pioneering Inc. Cambridge, MA

23.1M
Shares

$12.7 Million
3.73% of portfolio
Vanguard Group Inc Valley Forge, PA

6.06M
Shares

$3.33 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.76M
Shares

$969,186
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.39M
Shares

$763,751
0.0% of portfolio
Susquehanna International Group, LLP Bala Cynwyd, PA

1.19M
Shares

$656,011
0.0% of portfolio

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $68.2M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account